Results 241 to 250 of about 17,217,890 (291)
Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma [PDF]
Cancer Cell, 2021 ADAPTeR is a prospective, phase II study of nivolumab (anti-PD-1) in 15 treatment-naive patients (115 multiregion tumor samples) with metastatic clear cell renal cell carcinoma (ccRCC) aiming to understand the mechanism underpinning therapeutic response.
Elias P Pintus +2 more
exaly +2 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Combination therapies in non-clear-cell renal cell carcinoma
The Lancet Oncology, 2023We investigate the 1/Q^2 power-suppressed corrections to structure functionsin the flavour-singlet channel of deep inelastic lepton scattering arising fromrenormalon insertions into an initial-state gluon, as obtained using thedispersive approach. The pinch technique is used as a convenient tool in theseparation of contributions.
ÖZET, AHMET +3 more
openaire +3 more sources
Chemotherapy for Non–Clear-Cell Renal Cell Carcinoma
Clinical Genitourinary Cancer, 2006Clear-cell carcinoma is the most common histopathologic subtype of kidney tumors. Consequently, clinical trials for advanced-stage kidney cancer have focused on patients with clear-cell carcinoma and not on the less common subtypes, including papillary, chromophobe, collecting-duct carcinoma, and sarcomatoid-variant tumors.
Kevin A, David +2 more
openaire +2 more sources
Systemic Therapy for Non–Clear Cell Renal Cell Carcinoma
American Society of Clinical Oncology Educational Book, 2017Treatment options for metastatic clear cell renal cell carcinoma (ccRCC) have evolved markedly over the past decade, with multiple targeted therapies approved for the disease. In contrast, little improvement has been made in the management of metastatic non–clear cell RCC (nccRCC).
Tian, Zhang +3 more
openaire +2 more sources
Non–Clear Cell Renal Cell Carcinomas: From Shadow to Light
Journal of Clinical Oncology, 2018Non–clear cell renal cell carcinomas (RCCs) account for up to 25% of kidney cancers and encompass distinct diseases with distinct pathologic features, different molecular alterations, and various patterns of response to systemic therapies. Recent advances in molecular biology and large collaborative efforts helped to better define the oncogenic ...
Albiges, L +3 more
openaire +3 more sources
[Non-clear cell renal cell carcinoma].
Urologie (Heidelberg, Germany)Non-clear cell renal cell carcinomas (nccRCC) account for approximately 20-25% of renal cell carcinomas. Approximately 20 different histologically and/or molecularly defined entities are subsumed under nccRCC. Many entities only have a share of 1% or less.
Marit, Ahrens, Lothar, Bergmann
openaire +3 more sources
Non-Clear Cell Renal Cell Carcinoma - Pathology and Treatment Options
Oncology Research and Treatment, 2019Non-clear cell renal cell carcinomas (nccRCC) are rare diseases with heterogeneous histopathologically and genetically defined entities. The clinical data on optimal systemic treatments of nccRCC is rather limited. In this review, the current World Health Organization (WHO) classification of nccRCC based on histopathologic and genetic findings is ...
Marit, Ahrens +3 more
openaire +2 more sources
Comparing Everolimus to Sunitinib in Non–clear-cell Renal Cell Carcinoma
European Urology, 2016Compared to its more common clear-cell counterpart, metastatic non–clear-cell renal cell carcinoma (non-ccRCC) is less responsive to vascular endothelial growth factor (VEGF)-targeted therapy or inhibitors of the mammalian target of rapamycin (mTOR) [1]. It is unknown if VEGF targeting is superior to mTOR inhibition.
Axel, Bex, Börje, Ljungberg
openaire +2 more sources
Pathology and systemic therapy of non-clear cell renal cell carcinoma: an overview
Expert Review of Anticancer Therapy, 2021Introduction: Non-clear cell renal cell carcinoma (nccRCC) represents a highly heterogenous group of kidney cancer entities. As most clinical trials predominantly include patients with clear cell RCC (ccRCC), nccRCC treatment guidelines are mainly extrapolated from recommendations in ccRCC.
Lothar, Bergmann +3 more
openaire +2 more sources
Management of Non-clear Cell Renal Cell Carcinoma
2013Renal cell carcinoma comprises a large, heterogeneous group of tumors. Although clear cell renal cancer is the most common subtype, 20–25 % of renal malignancies are of variant histology. Papillary renal cell carcinoma represents the most common non-clear cell histology, with unclassified, chromophobe, collecting duct, and renal medullary carcinoma ...
Henry J. Conter +2 more
openaire +1 more source